Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

12.5%

1 terminated/withdrawn out of 8 trials

Success Rate

83.3%

-3.2% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A

5(71.4%)

Phase 2

2(28.6%)

7Total

N/A(5)

Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT05184270Not ApplicableCompleted

Integration of Auditory, and Deep Brain Stimulation to Enhance Deep Sleep in Parkinson's Disease

Role: lead

NCT04589182Not ApplicableUnknown

Assessing the Symptomatic Benefit of Acoustic Slow Wave Enhancement in Parkinson Disease

Role: lead

NCT03692962Not ApplicableCompleted

Decision-making After Sleep Restriction

Role: lead

NCT02070887Withdrawn

Inhibiting COMT in Parkinson's Disease

Role: lead

NCT01993680Phase 2Completed

Orthostatic Dysregulation and Associated Gastrointestinal Dysfunction in Parkinson's Disease -Treatment

Role: lead

NCT02111122Phase 2Completed

Study of the Symptomatic Effects of Nocturnal Sodium Oxybate in Parkinson's Disease

Role: lead

NCT02305225Not ApplicableCompleted

Cortical Excitability and Decision Making After Total Sleep Deprivation and Sleep Restriction

Role: lead

NCT03684603Not ApplicableUnknown

Acoustic Cueing During Slow-wave Sleep as a Measure to Improve Motor Rehabilitation Outcome in Stroke Patients

Role: lead

All 8 trials loaded